UNSPSC 51152051: Cisatracurium besilate

This classification denotes a nicotinic antagonist with the molecular formula C53H72N2O12.2C6H5O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 80YS8O1MBS, chemically known as isoquinolinium, 2,2-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate, (1r-(1alpha,2alpha(1r(sup *),2r(sup *))))- but more generally known as cisatracurium besilate, which bears US NIH Compound Identifier 62886.

UNSPSC 51152051 Cisatracurium besilate is a Commodity code that covers procurement of this specific neuromuscular blocking agent used in anesthesia and critical-care settings. Recent state and local opportunities tagged under this code show significant mismatch with the nominal pharmaceutical scope — the solicitations captured reflect procurement of naloxone (an opioid antagonist) and safe drug deactivation systems by a county health authority, and exploratory market research by a state health commission on direct-to-manufacturer prescription programs, neither of which directly involve cisatracurium besilate or its clinical use. The code appears to have limited or inconsistent application in state and local purchasing activity, with recent opportunities not aligned to the specific drug product.

Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; response deadline was July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor information on direct-to-manufacturer prescription program capabilities for a Therapeutic Pharmacy Initiative, with no formal evaluation timeline or award value specified at the exploratory stage. The geographic spread is limited to Florida and Texas based on recent activity, but the code shows little evidence of active procurement directly aligned to cisatracurium besilate as a pharmaceutical input.